News

Public · Published

InflaRx NV expected to post a loss of 6 cents a share - Earnings Preview

InflaRx NV is expected to report a fall in quarterly revenue for the period ending September 30, 2026, with results due November 3. LSEG's mean analyst estimate is a loss of 6 cents per share.

Published:

Updated:

What happened

InflaRx NV is expected to report a fall in quarterly revenue for the period ending September 30, 2026, with results due November 3. LSEG's mean analyst estimate is a loss of 6 cents per share.

Confirmed

Global impact / market context

An expected loss means analysts think costs will exceed revenue, which can reduce cash available to fund research. For a drug developer, continued losses may increase reliance on outside funding or future share sales, which can dilute existing owners.

Analyst inference

Analysts rate the shares a buy on average, with eight buy recommendations and none to hold or sell. The median 12-month price target of $8.50 sits far above the last closing price of $1.72, suggesting analysts see large potential upside.

Analyst inference

What to watch

  1. The company reports results on November 3 for the quarter ending September 30, 2026, and actual figures will show whether the 6-cent loss estimate was beaten, met, or missed. Confirmed
  2. Watch whether management proposes spending plans, financing needs, or changes to research programs, since these choices affect future cash needs and revenue prospects. Proposed
  3. Compare the reported loss with the prior quarter's loss and with the unchanged estimate, as a wider loss could signal higher costs or weaker revenue than analysts expect. Analyst inference

Evidence

  • Original source link unavailable